U.S. Stem Cell (USRM) Releases Quarterly Earnings Results
Shares of OTCMKTS:USRM opened at $0.08 on Tuesday. U.S. Stem Cell has a 52-week low of $0.02 and a 52-week high of $0.13. The company has a debt-to-equity ratio of -0.32, a quick ratio of 0.17 and a current ratio of 0.18.
COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2018/04/17/u-s-stem-cell-usrm-releases-quarterly-earnings-results.html.
U.S. Stem Cell, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for improving cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, lower limb ischemia, and rheumatoid arthritis.
Receive News & Ratings for U.S. Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.